MacroGenics Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics or view top-rated stocks.

Wall Street analysts have given MacroGenics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MacroGenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for MacroGenics.

MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Thursday, July, 29th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.38. The biopharmaceutical company had revenue of $30.76 million for the quarter, compared to analyst estimates of $35.55 million. MacroGenics had a negative trailing twelve-month return on equity of 41.16% and a negative net margin of 109.07%.
View MacroGenics' earnings history.

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MGNX shares have increased by 215.6% and is now trading at $20.48.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued twelve-month price targets for MacroGenics' stock. Their forecasts range from $17.00 to $41.00. On average, they expect MacroGenics' stock price to reach $34.40 in the next year. This suggests a possible upside of 68.0% from the stock's current price.
View analysts' price targets for MacroGenics or view top-rated stocks among Wall Street analysts.

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

Some companies that are related to MacroGenics include Alkermes (ALKS), Arvinas (ARVN), TG Therapeutics (TGTX), Schrödinger (SDGR), Hypera (HYPMY), Reata Pharmaceuticals (RETA), Turning Point Therapeutics (TPTX), Arena Pharmaceuticals (ARNA), Galapagos (GLPG), Karuna Therapeutics (KRTX), Prothena (PRTA), 23andMe (ME), ALX Oncology (ALXO), Zentalis Pharmaceuticals (ZNTL) and Cryoport (CYRX).
View all of MGNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bellevue Group AG (12.07%), RA Capital Management L.P. (9.73%), BlackRock Inc. (9.11%), Wasatch Advisors Inc. (6.74%), Vanguard Group Inc. (6.45%) and State Street Corp (5.29%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends for MacroGenics.

MGNX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Point72 Asset Management L.P., Bank of New York Mellon Corp, Opaleye Management Inc., Panagora Asset Management Inc., Bank of America Corp DE, and AXA S.A.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics or view top insider-selling stocks.

MGNX stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, RA Capital Management L.P., State Street Corp, RTW Investments LP, Victory Capital Management Inc., Commodore Capital LP, Lord Abbett & CO. LLC, and Woodline Partners LP.
View insider buying and selling activity for MacroGenics or or view top insider-buying stocks.

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGNX stock can currently be purchased for approximately $20.48.

MacroGenics has a market capitalization of $1.25 billion and generates $104.88 million in revenue each year. The biopharmaceutical company earns $-129,740,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.

MacroGenics employs 370 workers across the globe.

The official website for MacroGenics is www.macrogenics.com.

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at (301) 251-5172 or via email at [email protected]